ASLAN Strikes First Licensing Out Deal For Lead Project
This article was originally published in PharmAsia News
Executive Summary
Hyundai Pharm, a mid-sized South Korean pharma firm, is to license in local rights to Singapore venture ASLAN’s lead development molecule varlitinib, a novel small molecule pan-HER inhibitor for cholangiocarcinoma, in a move to boost its oncology pipeline.